Q-omics provides the consensus-scored DUSP18 profile across patient tissues and cancer cell-line models. DUSP18 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, DUSP18 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, DUSP18 RNA expression shows 20,006 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight SCLC, COAD, and KIRP as cancer lineages where DUSP18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DUSP18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DUSP18 survival associations across molecular data types. DUSP18 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DUSP18 RNA expression–survival associations across cancer types. High DUSP18 expression shows unfavorable associations in LIHC, KICH and ACC, but favorable associations in SCLC, THYM and BRCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for DUSP18 RNA expression.
This table summarizes DUSP18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for DUSP18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DUSP18 shows lower tumor expression in THCA and KICH and higher tumor expression in COAD, STAD, LIHC and HNSC. The COAD box plot shows higher DUSP18 RNA expression in tumor versus normal tissue (log2 FC = +0.895, t-test p < 0.001).
This table shows molecular features associated with DUSP18 in patient tissues and cancer cell lines. In patient samples, DUSP18 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, DUSP18 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
